3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Fatigue
6
Brain Neoplasms
3
Neoplasms
2
Depression
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Asthenia
2
Sleep Wake Disorders
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Neuroectodermal Tumors, Primitive
1
Meningioma
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Ependymoma
1
Cognitive Dysfunction
1
Astrocytoma
1
Interventions
acetaminophen, aspirin, caffeine drug combination
1
Transcranial Direct Current Stimulation
1
Sodium Chloride
1
Methylphenidate
1
G(M1) Ganglioside
1
Electroencephalography
1
Drug Delivery Systems
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Cognitive Dysfunction
×
Methylphenidate
×
Clear all
NCT02970500
2023-03-23
CogMet
CHU de Quebec-Universite Laval
Phase 2
Terminated
20 enrolled